Market Research Logo

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2018

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the Chronic Myelocytic Leukemia (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 29, 24, 20 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 4, 10 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bayer AG, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Co, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cell Medica Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectis SA, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GT Biopharma Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by H3 Biomedicine Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by IGF Oncology LLC, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Kiromic Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by LG Chem Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nohla Therapeutics Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Phylogica Ltd, H1 2018
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SELLAS Life Sciences Group Inc, H1 2018
List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report